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There has been an exponential increase in the number of
nephrological meta-analyses published, but their relative
contribution to the nephrology literature is unclear and
their influence on physician behavior and evidence-based
patient care is poorly understood. We studied the
nephrology literature, point-of-care resources, guidelines,
and a questionnaire survey of the New York Society of
Nephrology membership to understand the role and
perception of meta-analyses in nephrology. We discuss our
results in the context of the strengths and limitations of
meta-analyses and their relatively limited, albeit increasing
influence on published guidelines and on point-of-care
references. The results of our practitioner survey and our
review of the nephrology literature suggest an increasing
influence at the level of the individual practitioner of
meta-analyses. This underlines the need to develop a better
understanding of the contributions and role of meta-analyses
in the literature.
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The practice of combining data from different studies was
initially described in the field of astronomy by Gauss and
Lapace and was disseminated in the first textbook in the field
in 1861.1,2 The earliest attempt to actually combine data from
different studies was performed by Karl Pearson in 1904. The
term ‘meta-analysis’ was coined much later by Glass in 1976
but the first meta-analyses in medicine did not appear till
several years later.2–4 Since the first meta-analysis in
nephrology in 1987, there has been a rapid growth in the
number of papers dealing with meta-analyses in the field.5–10
However, meta-analyses are not immune from bias, error,
limited generalizability, or the inclusion of poor data.11,12
Meta-analyses are considered a subtype of systematic
reviews with statistical pooling of data from reviewed studies,
while at the same time they are also considered a form of
original research.2 The contribution of meta-analyses to the
nephrology literature remains unclear and their influence on
physician behavior and evidence-based patient care is poorly
understood. Although they are used primarily to generate a
single estimate of treatment effect, they are also considered
useful for assessing sources of variation among clinical trials
with differing results and testing new hypotheses. Although
the impact of this statistical tool in the field of nephrology
has been estimated previously, we attempt to develop an
understanding of physician perceptions of the relative
importance of meta-analyses as well as the likely impact on
patient care.9
We reviewed the meta-analyses published in four clinical
nephrology journals with the highest 2008 impact factors—
Journal of the American Society of Nephrology, Kidney
International, American Journal of Kidney Diseases, and
Nephrology Dialysis and Transplantation. In addition, the
contributions of meta-analyses to patient care were assessed
by reviewing the reporting of papers dealing with meta-
analysis among the various clinical nephrology guidelines
including KDOQI (Kidney Disease Outcomes Quality
Initiative), KDIGO (Kidney Disease: Improving Global
Outcomes), ERA-EDTA (European Renal Association–
European Dialysis and Transplant Association), and CARI
(Caring for Australasians with Renal Impairment). Articles
on the management of lupus nephritis and the prevention of
contrast nephropathy in UpToDate were reviewed to assess
the influence of meta-analyses on popular point-of-care
resources. Finally, we surveyed the membership of the New
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York Society of Nephrology (NYSN) to understand the
general perception that members of these nephrology-
focused associations have of meta-analyses using a nine-
question anonymous survey that was disseminated by email
(see Supplementary Appendix). We received 175 responses
from approximately 350 people to whom the email was sent,
for an approximate response rate of 50%.
Meta-analyses and the nephrology literature
We found a rapid increase in the number of meta-analyses
published in the most influential nephrology journals that
paralleled a similar increase in the literature (Figure 1).
Between 1991 and 1995, the four leading journals published
just seven meta-analyses between them, whereas in 2008
alone, there were 16 in the same journals. Of note, this
increase was even greater if the Clinical Journal of the
American Society of Nephrology was included (4 in 2008 and
11 in the first 10 months of 2009). Part of the recent increase
in meta-analyses in the nephrology literature was contributed
to by the establishment of the Cochrane Renal group in
1997.6,13 Our search revealed that a relatively small set of
authors appeared to be responsible for a vast majority of the
meta-analyses. For example, a single author participated in
73 nephrology meta-analyses since 2000, including 45
published in the Cochrane database (of which 11 were
updates of earlier meta-analyses). Another author partici-
pated in 15 additional analyses (not part of the 73 above),
including 1 published in the Cochrane database between
2004 and 2010.
We searched the nephrology literature for examples of
meta-analyses that were performed contemporaneously and
found several. However, we chose to focus on two instances
of such meta-analyses on the benefit of sodium bicarbonate
in the prevention of contrast nephropathy—the first in
September 2008 and the second between November 2009 and
January 2010.14–17 The first pair of meta-analyses included a
similar, but not identical, set of studies and came to the same
conclusion of superiority of sodium bicarbonate in the
prevention of contrast nephropathy.14,15 The second pair of
meta-analyses also included a similar set of studies;
specifically, the meta-analysis published in November 2009
included nine peer-reviewed publications and 14 reports that
were either published only as abstracts or conference
proceedings or obtained directly from the investigators.17
This analysis concluded that the benefit of bicarbonate-based
therapy was uncertain.17 The more recent meta-analysis
however included only seven peer-reviewed publications (all
included in the other analysis) and concluded that bicarbo-
nate was superior to saline in the prevention of contrast
nephropathy.16 Although contradictory, the reasons for the
differing conclusions are obvious on a comparison of these
studies. The first analysis demonstrated a benefit when
restricting the analysis to only peer-reviewed articles similar
to the latter analysis, but the benefit disappears on including
the data from the ‘gray literature’.17
Influence of meta-analyses on guidelines and patient care
resources
Review of nephrology guidelines published by various
organizations, including KDOQI, KDIGO, and EBPG
(European Best Practice Guidelines), showed the relative
infrequency of references to meta-analyses. The KDOQI
guidelines each had between 0 and 9 meta-analyses (0–1.5%
of all references) and demonstrated a trend of increasingly
referencing meta-analyses as a source of evidence over time
(see Figure 2). KDOQI guidelines published in 2000
referenced two meta-analyses (0.6% of all references) whereas
the KDOQI diabetes guidelines referenced nine meta-analyses
(1.5% of all references). Although this may reflect a relative
paucity of meta-analyses in the nephrology literature, we
found examples of meta-analyses that were in agreement with
the recommendations that were not referenced.18
UpToDate is a popular bedside electronic resource of
evidence-based medicine that is widely used by practicing
nephrologists in the United States. Meta-analyses were
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Figure 1 | Exponential increase in published meta-analyses in
the four leading nephrology journals.
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Figure 2 |Mean number of meta-analyses referenced in the
Kidney Disease Outcomes Quality Initiative (KDOQI)
guidelines expressed as a percentage of all references
included in guidelines published that year.
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referenced variably and with no clearly discernible pattern by
authors of nephrology-related articles in this popular point-
of care-database—perhaps reflective of author preference and
the literature rather than an editorial choice.19,20 This was
best exemplified by the article on contrast nephropathy that
referenced 16 systematic reviews and/or meta-analyses,
whereas only 2 meta-analyses were referenced between the
three articles on the management of lupus nephritis.19–22
Nephrologist perception of meta-analyses
We disseminated a 9-question survey by email and received
174 responses including 24 incomplete questionnaires. Our
questionnaire assessed the perceived role of meta-analyses in
evidence-based medicine and clinical guidelines and asked
respondents to rank different types of study designs in the
area of lupus nephritis. In addition, we asked them to
determine how they would respond to a meta-analysis on the
use of sodium bicarbonate for contrast nephropathy, while
also attempting to determine if respondents recognized a
change in their practice patterns based on a meta-analysis.
The overwhelming majority of our respondents were
physicians (95.4%) practicing academic medicine (97.6% of
physicians; Figure 3a). Most respondents reported being in
practice for X10 years (46.6%), whereas only a minority of
respondents were still in training (11.5%; Figure 3b). Almost
half (46%) the respondents also reported having received
some formal training in either statistics or research
methodology.
We compared the relative ranking of different study
designs by respondents with and without training in statistics
or research methodology (Figure 4 and Table 1). Overall,
respondents with formal training were significantly more
likely to pick either a systematic review or a meta-analysis as
being the most influential study design (60 vs 43.2%,
P¼ 0.043). Surprisingly, 36.7% of all respondents rated
meta-analyses over other study designs including randomized
controlled trials (RCTs; see Figure 4).
Respondents with formal training were also more likely to
give equal importance to RCTs and meta-analyses than those
without formal training—consistent with the difference in
opinion described earlier. However, this difference did not
reach significance (33.8 vs 20.7%, P¼NS). When subdivided
by type of practice, these differences persisted among
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Figure 3 |NYSN survey respondent characteristics.
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(b) Duration in practice as reported by respondents to our survey.
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Figure 4 |Ranking of different study designs in degrees of
relative influence by survey respondents.
Table 1 | Comparison of relative ranking of different study
designs by individuals with and without formal training in
either statistics or research methodology
Study ranked as being most influential Statistical training
Yes No Total
Nonacademic
practice
Observational study 0 1 1
Randomized controlled trial 5 7 12
Meta-analysis 2 3 5
Systematic review 1 3 4
Total 8 14 22
Academic practice* Observational study 0 3 3
Randomized controlled trial 18 29 47
Meta-analysis 28 19 47
Systematic review 8 9 17
Total 54 60 114
All respondents Observational study 0 4 4
Randomized controlled trial 28 42 70
Meta-analysis 33 23 56
Systematic review 10 12 22
Total 71 81 152
*Po0.05.
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practitioners in academic practices only. Formal research
methodology training did not appear to impact the opinion
of those who reported being part of a nonacademic practice
(Table 1).
Interestingly, there were similar proportions of respon-
dents with formal training in academic and nonacademic
practice (48.4 vs 31%, P¼NS), but respondents working in
academic settings were more likely than those in nonaca-
demic settings to rate meta-analyses and systematic reviews
as being more influential than RCTs (Table 1). Formal
training in statistics or research methodology was not likely
to change whether a meta-analysis had influenced patient
care (46.8 vs 57.3%, P¼NS; Figure 5). Despite the high
perceived value of this study design, when respondents were
asked to rank various studies in order of relative influence, a
majority (64.9%) did not think that they should be given the
same level of importance as RCTs. However, the high
perceived value was inconsistent with the preference among
respondents for the result of the meta-analysis in favor of
bicarbonate infusions for contrast-induced nephropathy even
when individual RCTs failed to show a benefit. Among the
respondents who thought that meta-analyses should get at
least equal importance, only 13.2% ranked RCTs as the most
influential design; 71.1% ranked meta-analyses as the most
influential followed by 15.1% who ranked systemic reviews
as the most influential (Table 2). These respondents were also
significantly more likely to use the results of the bicarbonate
meta-analysis than those who did not view meta-analyses
as favorably (75.6 vs 51.8%, P¼ 0.006) and more likely
to report that meta-analyses were an important source of
evidence-based medicine that should influence clinical
guidelines (92.5 vs 57.6%).
Among respondents who felt that meta-analyses and RCTs
should be given equal importance, 75.6% were in favor of the
use of positive results of the bicarbonate meta-analysis,
whereas a surprising 51.8% of respondents who did not give
them equal importance also favored using the results of the
meta-analysis over those of the individual results (P¼ 0.006).
In addition to the survey, we also communicated with
several principal investigators of large RCTs in nephrology
that attempted to address questions that were asked in the
form of a meta-analysis either before or during the clinical
trial. Their responses indicated that the results of meta-
analyses were unlikely to influence the study design of
subsequent RCTs and, moreover, they did not appear to
prompt any additional interim analyses when published
meta-analyses reported an increase in adverse outcomes.
RCTs, regardless of size, appear to be perceived as ‘more
impressive and of greater influence’ than meta-analyses.
Comparison with narrative review
Narrative reviews are often inefficient, subjective (thus prone
to bias and error), and scientifically unsound. These
deficiencies make a standardized appraisal of the literature
coupled with a systematic integration of the data significantly
more appealing.23,24 Problems with narrative reviews have
shown only a marginal improvement in methodology in a
subsequent review performed a decade later but they
continue to have advocates who support the role of this
type of review in the literature.25,26 Meta-analyses are a type
of systematic reviews that, although retaining the purported
advantages over the standard narrative review, are subject to
stringent mathematical presumptions and procedures. The
core of meta-analysis is a systematic approach to the
identification and abstraction of critical information from
earlier research.26 Meta-analyses attempt to create a single
summary statistic for the effect size of studies, which in turn
is a reflection of the magnitude of the treatment effect of a
study while accounting for the precision and the resulting
relative weight of the individual studies.27 As a result, meta-
analyses are rated by some as the highest grade of evidence.28
The frequency of meta-analyses and systematic reviews for
questions of therapy have been increasing both in the general
medical and the nephrology literature, despite the relative
paucity of RCTs in nephrology.7,29 In recognition of the
recent increase in meta-analyses and systematic reviews and
their role as an integral part of the literature, attempts to
standardize and improve their reporting have been made
with the QUOROM (Quality of Reporting of Meta-Analyses)
and the more recently updated PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guide-
lines.7,30–32 The recent PRISMA statement on the reporting of
systematic reviews and meta-analysis stated ‘Systematic
reviews and meta-analyses are essential to summarize
evidence relating to efficacy and safety of health care
interventions accurately and reliably’.31 However, their
perceived role by readers of the nephrology literature has
been unclear and may not be congruent with their true
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Figure 5 |Perception of meta-analyses among NYSN survey
respondents. (a) Responses when asked if meta-analyses are
original research similar to randomized controlled trials.
(b) Response to whether respondents considered meta-analyses a
source of evidence-based medicine. (c) Responses to whether
respondents have had meta-analyses directly influence their
patient care.
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contributions to the literature. This is especially concerning
with the widespread presence of major methodological flaws
in meta-analyses published in nephrology.7,33
Limitations of meta-analyses
Meta-analyses have not been without controversy and
criticism; they have been referred to as ‘mega-silliness’,
‘statistical alchemy’, ‘meta-analysis/shemeta-analysis’, and
even a ‘marketing weapon’, while also being compared with
cinnamon and metaphysics in addition to their trust-
worthiness being called into question.8,12,34–38 The apparent
disproportionate increase in popularity of meta-analyses
relative to RCTs has occurred despite suggestions to ‘not view
results uncritically’ and criticism of the inconsistencies
in quality recently.39,40 Despite recent improvements in
methodology, the use of the results of meta-analyses
preferentially in areas where an adequately powered RCT
exists, by clinicians, raises important questions and ought to
be discouraged.41,42
The current environment favoring evidence-based prac-
tices and comparative effectiveness research requires an
understanding of the role of meta-analyses and their true
place in the hierarchical system of evidence by readers. The
statistical and methodological complexity of this form of
analysis makes this a challenge—one that is underlined by a
recent article that demonstrated numerous methodological
problems with a meta-analysis by an American College of
Chest Physicians/American Association for Respiratory
Care/American College of Critical Care Medicine Task Force
on ventilator weaning among others.43
The placement of meta-analyses at the pinnacle of this
hierarchy without consideration of the relevant similarity of
the primary studies included in the analyses is questionable.28
A recent observation that meta-analyses selected for publica-
tion are not necessarily methodologically superior to those
that are not underlines the need for the reader to be more
discriminating.44 The necessity for a better understanding is
perhaps even more urgent with the recent introduction of
umbrella reviews and network meta-analyses to the growing
heterogeneity of the evidence base for clinicians.45
In addition, like narrative reviews, meta-analyses are also
liable to numerous sources of bias and error—both at the
level of the individual trial and the dissemination of trial
results that can result in erroneous or varied conclu-
sions.23,26,46 Some meta-analyses suffer from carelessness
and inadequate care to observe the most elementary
precautions.47 Other potential sources of errors/bias in
meta-analyses include:
(1) File drawer problems or publication bias: This refers to
the established practice of selective reporting of studies
with significant results.48 Although this problem affects
the conduct of clinical trials as well as narrative reviews,
its impact on meta-analyses has received special atten-
tion. The discordant results seen in the recent meta-
analyses of sodium bicarbonate for contrast nephropathy
are an example of this bias.16,17 Mathematical modeling,
simple graphical tests, and iterative correction proce-
dures have been developed for this bias.49,50 Unfortu-
nately, these tests are often not applied appropriately,
thereby negating any potential benefit that these
statistical procedures may provide.51 Additionally, up-
dating of meta-analyses further inflates the type I error
associated with publication bias and this is of particular
concern when 23% of these analyses are updated within 2
years of publication.52,53 The problem of covert duplicate
publication has the exact opposite impact and in at least
one case has been shown to exaggerate the efficacy of a
treatment.54
(2) Mixing apples and oranges: Meta-analyses almost always
address questions that are broader than those asked by
Table 2 | Comparison of whether respondents with and without formal training would give equal importance to meta-analyses
and randomized controlled trials
Equal importance
Yes No Total P-value
Statistical training Yes 24 47 71
No 17 65 82 Po0.05
Ranking Observational study 0 4 4
Randomized clinical trial 6 64 70
Meta-analysis 29 27 56
Systematic review 6 16 22
Total 41 111 152 Po0.001
Bicarbonate Yes 31 58 89
No 10 54 64
Total 41 112 153 Po0.05
Should influence guidelines Yes 38 64 102
No 3 48 51
Total 41 112 153 Po0.05
Impacted patient care Yes 30 49 79
No 0 19 19
Unsure 11 44 55
Total 41 112 153 Po0.05
Also shown is a comparison of how respondents who thought that meta-analyses should be given equal importance responded to other questions compared with those who
did not.
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individual studies included.55 However, there tends to
be both clinical and statistical heterogeneity among
studies—both of which are a significant problem.56,57
Whether the results of a meta-analyses can be generalized
depends in part on the consistency of the results of the
individual studies included. Statistical heterogeneity can
be identified and addressed with the use of various
statistical measures such as the I2 statistic but identifying
and addressing clinical heterogeneity poses a significant
challenge in the absence of patient-level data.57,58 Failure
to identify important clinical differences in the patient
populations included in a meta-analysis can result in
misleading outcomes.59
(3) GIGO (Garbage In, Garbage Out): The clinical trials
included in meta-analyses should ideally be of high
methodological quality, but evaluations of studies included
in published meta-analyses find serious limitations in the
included trials.60 The inclusion of trials with inherent
design flaws or biases may exaggerate potential errors in
meta-analyses and systematic reviews that include them.61
(4) Outcome selection bias: This results from the selection
of a subset of the original variables recorded for inclusion
in publication of trials.62,63 The selective reporting
of data in trials is widespread but this potential bias
does not appear to have significantly impacted recent
meta-analyses.62 In addition, this potential bias can be
overcome with the use of patient-level data.63
(5) Patient exclusion bias or attrition bias: This refers to the
post-randomization exclusion of patients in included
trials. The wide variation in the percentage of patients
excluded in trials favors the research intervention more
frequently. Combining these estimates in a systematic
review or meta-analysis may aggregate these biases.64
(6) Truncated study bias: The inclusion of studies that were
stopped prematurely because of perceived benefit may inflate
the treatment effect. However, frequently the risk of over-
estimation of the treatment effect introduced by including
these studies is overlooked in published meta-analyses.65
(7) Errors in data collection and extraction: Reviews of
published meta-analyses have demonstrated errors in
the application of eligibility criteria to identify trials
for inclusions as well as the extraction of data from
included trials.66–68 Errors of omission as well as errors of
inaccuracies appear to be commonplace even among
reviews published by the Cochrane group.67,69,70 Errors
rates for data inclusion did not appear to diminish with
increasing experience of the reviewers and a second data
extraction does not appear to impact errors of omis-
sion.67,69 Significant deviations in the final point
estimate resulting from these point estimates have also
been demonstrated.66,67
Benefits of meta-analyses
There are several potential benefits of meta-analyses that are
frequently cited by proponents who place meta-analyses at
the pinnacle of the hierarchy of evidence-based medicine.28,71
Potential benefits include:
(1) Increasing the power of studies: The inclusion of several
studies and the resultant pooling of patients increase the
statistical power. In addition, using any single study to
support the use of any therapy has its inherent
limitations.72,73 The prevalence of inadequately powered
studies and the associated false-negative rate in clinical
trials has not changed over time.73 However, it must be
noted that there is an understated qualitative difference
between meta-analyses that use aggregated data and
those that use individual data—a distinction that has
resulted in different and often misleading conclu-
sions.74–76
(2) They highlight areas where there is a lack of adequate
evidence and thus identify where further studies are
needed.
(3) Meta-analyses are a more transparent form of review of
the existing literature, allowing readers to identify
sources of conclusions.72
(4) Meta-analyses offer a sounder basis for subgroup
analyses, particularly if they are based on individual
participant data. This can be achieved by identifying
reasons for heterogeneity (inconsistency in results across
studies), thereby assisting in generation of new hypoth-
esis about specific subgroups.77 However, subgroup
analysis should always be considered with caution.78
Critics of meta-analyses view it more as a valuable
objective descriptive technique, which often furnishes clear
qualitative conclusions, but are more reserved about the
acceptance of its quantitative conclusions.34 Although meta-
analyses do not agree with subsequent large RCTs 35–40% of
the time, they have been shown to agree with subsequent
large trials more often than would be expected by chance.79–81
Interestingly, about a third of RCTs are also reported to fail to
match the next RCT on the same topic.55 Meta-analysis
techniques continue to improve and be refined in several
respects, thus improving their value.10
The results of our survey show how meta-analyses are
perceived among practicing nephrologists who are members
of the NYSN. Although this group of nephrologists may
not be representative of the nephrology community at large,
we found that a majority report their acceptance of
meta-analyses, approve of their influence on guidelines and
believe that they have influenced their care of patients—all
while not considering them to be as important as RCTs.
Consistent with this, we noted an increasing number of
meta-analyses referenced by the KDOQI guidelines over time.
Although this might just be a reflection of the increasing
number of meta-analyses in the literature, it is also likely to
be a reflection of the greater acceptance of meta-analyses by
authors of these guidelines. The possibility of increasing
acceptance is supported by the absence of relevant meta-
analyses from the earlier guidelines.18 We attempted to
test the suggestion that the meta-analyses are hypothesis
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generating and influence subsequent research. Clinical
investigators interviewed by us toward this end suggested
that although they were aware of relevant meta-analyses in
the literature, these analyses did not influence their design of
subsequent clinical trials.
Conclusion
Meta-analyses are becoming more common in the nephrol-
ogy literature. Although they provide certain benefits, they
are prone to multiple errors and sources of bias. They are yet
to have a significant direct impact on clinical guidelines, but
they are being increasingly referenced and appear to be
influencing popular point-of-care resources. In addition, they
appear to be popular among nephrologists as a source of
evidence-based information and appear to influence patient
care at the level of the individual practitioner.
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